Assessment of Vitamin D Metabolism in Patients with Cushing's Disease in Response to 150,000 IU Cholecalciferol Treatment
Povaliaeva A, Bogdanov V, Pigarova E, Zhukov A, Dzeranova L, Belaya Z, Rozhinskaya L, Mel'nichenko G, Mokrysheva N
Nutrients · 7 citations
How it was studied
- Design
- Case-control study (indexed by PubMed)
- Studied in
- People
- Main outcome
- Health markers and function
Who paid for it
- Funding
- Independent funding
- Government
- Russian Science Foundation
- Grants
- Russian Science Foundation (19-15-00243)
Based on 1 listed funder(s).
Publication
- Published
- 2021-11-30 · Nutrients · vol. 13 · issue 12 · p. 4329
- Publisher
- Multidisciplinary Digital Publishing Institute
- Cited
- 10 citations · more than 75% of similar papers · 1.0× the field average
- References
- 54 works
- Access
- Open access (journal) · CC-BY
- Research areas
- Vitamin D Research Studies · Pituitary Gland Disorders and Treatments · Bone health and osteoporosis research
- Keywords
- Cholecalciferol, Vitamin D and neurology, Medicine, Endocrinology, Cushing's disease, Internal medicine, Vitamin, Metabolism, Cushing syndrome, Disease
- MeSH
- humans, pituitary acth hypersecretion, cholecalciferol, hydrocortisone, parathyroid hormone, vitamins, vitamin d, serum albumin, vitamin d-binding protein, treatment outcome, case-control studies, adult, middle aged, female, male
9 authors
From RU
- Alexandra A. Povaliaeva · correspondingEndocrinology Research Center
- Viktor P. BogdanovEndocrinology Research Center
- Ekaterina Aleksandrovna PigarovaEndocrinology Research Center
- Artem Yu. ZhukovEndocrinology Research Center
- Larisa Konstantinovna DzeranovaEndocrinology Research Center
- Zhanna E. BelayaEndocrinology Research Center
Abstract
In this study we aimed to assess vitamin D metabolism in patients with Cushing's disease (CD) compared to healthy individuals in the setting of bolus cholecalciferol treatment. The study group included 30 adults with active CD and the control group included 30 apparently healthy adults with similar age, sex and BMI. All participants received a single dose (150,000 IU) of cholecalciferol aqueous solution orally. Laboratory assessments including serum vitamin D metabolites (25(OH)D3, 25(OH)D2, 1,25(OH)2D3, 3-epi-25(OH)D3 and 24,25(OH)2D3), free 25(OH)D, vitamin D-binding protein (DBP) and parathyroid hormone (PTH) as well as serum and urine biochemical parameters were performed before the intake and on Days 1, 3 and 7 after the administration. All data were analyzed with non-parametric statistics. Patients with CD had similar to healthy controls 25(OH)D3 levels (p > 0.05) and higher 25(OH)D3/24,25(OH)2D3 ratios (p p p > 0.05) and lower albumin levels (p 3/24,25(OH)2D3 ratio (r = 0.36, p 3 after cholecalciferol intake was similar in obese and non-obese states and lacked correlation with BMI (p > 0.05) among patients with CD, as opposed to the control group. Overall, patients with CD have a consistently higher 25(OH)D3/24,25(OH)2D3 ratio, which is indicative of a decrease in 24-hydroxylase activity. This altered activity of the principal vitamin D catabolism might influence the effectiveness of cholecalciferol treatment. The observed difference in baseline free 25(OH)D levels is not entirely clear and requires further study.
Abstract via Europe PMC. Copyright remains with the authors or publisher (CC BY).
Community trust
Loading…
How much do you trust this study's findings?
Comments
Sign in to rate, comment on or flag this study.Sign inSomething wrong here?
Flag this study if its information, labels or funding look wrong. An editor reviews every flag.
Sign in to rate, comment on or flag this study.Sign inEducational information about published research. Not medical advice, and not a recommendation to start or stop anything.